<DOC>
	<DOCNO>NCT00991861</DOCNO>
	<brief_summary>The aim study determine efficacy , safety tolerability either twice daily topical application LAS41007 compare twice daily application LAS106521 treatment actinic keratosis .</brief_summary>
	<brief_title>Efficacy Safety Study LAS41007 Treatment Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>At least 410 clinically assess actinic keratosis grade I II ( accord Olsen et al , 1991 ) face/forehead and/or bald scalp The diameter AK target lesion le 0.5 cm great 1.5 cm The target lesion must locate overall 2 treatment area size 25 cm2 per treatment area Have evidence clinically significant unstable medical condition : metastatic tumor tumor high probability metastatic spread heart failure ( NYHA class III high ) immunosuppressive disorder ( e.g . HIV ) hematologic , hepatic , renal , neurologic endocrine disorder . collagenvascular disorder ( e.g . cerebrovascular disorder bleeding ) . gastrointestinal disorder ( e.g . active ulcera history recurrent peptic ulcera hemorrhage ) Suffer paresthesia treatment area Show Cornu cutaneum skin and/or hypertrophic AK lesion treatment area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>AK</keyword>
	<keyword>NMSC</keyword>
</DOC>